Pancreatic Cancer Research

ResearcherMassachusetts Institute of TechnologyActive in the last 2 years

Giulia Biffi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4592-0970; OpenAlex author ID A5067376769. Sources: OpenAlex.

Their work

Papers
24 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
110
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 5 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 5 papers · 2025: 1 paper · 2026: 5 papers

Papers 24

  1. Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis. Last author DOI 10.1038/s41556-026-02057-w↗
  2. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  3. Lung Metastases in Pancreatic Cancer: Timing Their First Breath. First author DOI 10.1158/0008-5472.can-25-4465↗
  4. Cross-species graph-embedding unmasks the ageing microenvironment as a key determinant of pancreatic cancer malignant cell biology and therapy response Last author DOI 10.64898/2026.02.02.703350↗
  5. TGF-β- and IL-1-dependent fibroblast states differentially shape pancreatic cancer microenvironments and metastasis Last author DOI 10.64898/2026.09.08.750042↗
  6. SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-2330↗
  7. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Last author DOI 10.1016/j.ccell.2023.12.002↗
  8. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  9. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  10. Cancer-Associated Fibroblasts: From Spectators to Protagonists in Pancreatic Cancer Progression. Last author DOI 10.1158/0008-5472.can-24-2448↗
  11. Modelling the micro- and macro- environment of pancreatic cancer: from patients to pre-clinical models and back. Last author DOI 10.1242/dmm.050624↗
  12. Tracing back to one of the origins of immune evasion in pancreatic cancer. First author DOI 10.1016/j.ccell.2022.05.002↗
  13. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-20-3715↗
  14. Tracing the Origin of Fibroblasts in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2020.06.008↗
  15. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. First author DOI 10.1084/jem.20192389↗
  16. Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models Co-author DOI 10.1101/2020.09.10.292193↗
  17. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. First author DOI 10.7554/elife.53381↗
  18. Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.7554/elife.56782↗
  19. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-18-0710↗
  20. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  21. A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth. Co-author DOI 10.1158/2159-8290.cd-19-0273↗
  22. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  23. Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2016.50↗
  24. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gianluca Mucciolo · 7 shared papers, 2024–2026 · strength 2.06
  2. Joaquín Araos Henríquez · 8 shared papers, 2022–2026 · strength 1.92
  3. Eloise G. Lloyd · 6 shared papers, 2024–2026 · strength 1.43
  4. David Arthur Tuveson · 12 shared papers, 2015–2024 · strength 1.15
  5. Priscilla S.W. Cheng · 5 shared papers, 2024–2026 · strength 1.07
  6. Wenlong Li · 4 shared papers, 2024–2026 · strength 1.01
  7. Rebecca J. Brais · 3 shared papers, 2025–2026 · strength 0.65
  8. Youngkyu Park · 7 shared papers, 2015–2024 · strength 0.58
  9. Debasmita Mukherjee · 2 shared papers, 2026 · strength 0.46
  10. Tobiloba E. Oni · 6 shared papers, 2015–2021 · strength 0.44
  11. Vincenzo Corbo · 4 shared papers, 2015–2025 · strength 0.44
  12. Ela Elyada · 6 shared papers, 2015–2021 · strength 0.42
  13. Jens Thomas Siveke · 2 shared papers, 2024–2026 · strength 0.39
  14. Hao Yuan · 5 shared papers, 2015–2021 · strength 0.37
  15. Lisa Veghini · 2 shared papers, 2024–2025 · strength 0.36
  16. Daniel Öhlund · 4 shared papers, 2015–2024 · strength 0.34
  17. Vinod P. Balachandran · 1 shared paper, 2026 · strength 0.24
  18. Miriam Klauß · 1 shared paper, 2026 · strength 0.24
  19. Thierry Conroy · 1 shared paper, 2026 · strength 0.24
  20. Susanne Roth · 1 shared paper, 2026 · strength 0.24
  21. Efrat Dotan · 1 shared paper, 2026 · strength 0.24
  22. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.24
  23. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.24
  24. Minoti Vivek Apte · 1 shared paper, 2026 · strength 0.24
  25. Núria Malats · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.